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BACKGROUND: Noninvasive prenatal diagnosis of monogenic disorders using maternal 
plasma and targeted massively parallel sequencing is being investigated actively. We 
demonstrated previously that comprehensive genetic diagnosis of a Duchenne muscular 
dystrophy (DMD) patient is feasible using a single targeted sequencing platform. In the 
present study, we demonstrate the applicability of this approach to carrier detection and 
noninvasive prenatal diagnosis. 
METHODS: Custom solution-based target enrichment was designed to cover the entire DMD 
region. Targeted massively parallel sequencing was performed using genomic DNA from four 
mother and proband pairs to test whether carrier status could be detected reliably. Maternal 
plasma DNA at varying gestational weeks was collected from the same families and 
sequenced using the same targeted-platform to predict the inheritance of the DMD mutation 
by their fetus. Overrepresentation of an inherited allele was determined by comparing the 
allele fraction of two phased haplotypes after examining and correcting for the recombination 
event. 
RESULTS: The carrier status of deletion/duplication and point mutations was detected reliably 
through using a single targeted massively parallel sequencing platform. Whether the fetus had 
inherited the DMD mutation was predicted correctly in all four families as early as 6 weeks 
and 5 days of gestation. In one of these, detection of the recombination event and 
reconstruction of the phased haplotype produced a correct diagnosis.  
CONCLUSIONS: Noninvasive prenatal diagnosis of DMD is feasible using a single targeted 
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Discovery of the presence of cell-free fetal DNA (cffDNA) in maternal plasma offers a 
powerful tool for the development of noninvasive prenatal genetic diagnosis (1). The 
application to prenatal diagnosis has been accelerated by the introduction of massively 
parallel sequencing technology (2, 3). Prenatal tests capable of detecting aneuploidies using 
cffDNA have been commercialized and are highly sensitive and accurate (4). Several studies 
have confirmed the accuracy of whole-genome sequencing and sequencing after target 
enrichment of cffDNA by demonstrating the relatively even distribution of fetal and maternal 
DNA across the entire genome (5–7). This result provides the basis for extending the 
applications to monogenic disorders, which comprise a larger proportion of genetic diseases 
than chromosomal aneuploidies. 
However, unlike the rapid incorporation of aneuploidy detection into clinical practice, the 
application to monogenic disorders is far more complex and has many obstacles to overcome. 
Technically, the low and variable fraction of cffDNA in maternal plasma limits the reliable 
detection of fetal variants at the single-nucleotide level. Moreover, complex ethical and 
socioeconomic issues limit the implementation of noninvasive genome-wide screening in the 
prenatal diagnosis of monogenic disorders in pregnant women without a known increased 
risk. Therefore, for clinical applications, the ideal platform needs to be a targeted design that 
can ensure deep coverage and be equally applicable to the proband and carrier, and for 
prenatal diagnosis. 
We have developed a method that allows the comprehensive genetic diagnosis of a Duchenne 
muscular dystrophy (DMD) patient. We have shown that this method is feasible when used 
with a targeted massively parallel sequencing platform (8). Targeting the entire exonic and 
intronic regions produced nearly continuous uniform coverage across the DMD gene, 
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enabling identification of both large deletions/duplications and point mutations. Because this 
method is sensitive enough to detect a dosage imbalance, the mother’s carrier status could be 
easily identified with the same approach. In addition, because about 1,000 heterozygote sites 
could be used to analyze maternal X alleles at two phases, this method may be also applicable 
to prenatal diagnosis using cffDNA by detecting haplotype imbalances between two phased 
haplotypes in the DMD gene. This haplotype-based imbalance analysis via either whole-
genome sequencing or targeted sequencing of maternal plasma DNA has been substantiated 
in models of several diseases, including beta-thalassemia, congenital adrenal hyperplasia, and 
congenital deafness (5, 9-11). Specifically, New et al. adopted a similar approach using 
targeted sequencing and a tiling design for the noninvasive prenatal diagnosis of congenital 
adrenal hyperplasia inherited with an autosomal recessive pattern (11). 
In the present study, we attempted to demonstrate the feasibility of using the targeted 
massively parallel sequencing platform for carrier detection and noninvasive prenatal 











MATERIAL AND METHODS 
PATIENTS 
The four DMD families receiving a prenatal diagnosis were prospectively recruited. Each 
family cohort consisted of a proband and the carrier mother. DMD mutations in the families 
included both large deletion/duplication and point mutations (Table 1). The experiment was 
designed and performed in two parts. First, genomic DNA from four mother and DMD 
proband pairs were sequenced to test whether an inherited DMD mutation from the carrier 
mother could be detected confidently. Second, maternal plasma DNA from the four carrier 
mothers at varying weeks of gestation was sequenced to determine whether inheritance of a 
DMD mutation from a carrier mother could be predicted in her fetus. Fetal genomic DNA 
obtained from either, chorionic villi sampling or amniocentesis was used to validate the 
results of the maternal plasma DNA sequencing. All procedures were performed as routine 
prenatal diagnosis. Additional informed consent was obtained for the study that used maternal 
plasma DNA and fetal DNA. The institutional review board approved the study protocol (IRB 
No. 1302-055-464). 
TARGET ENRICHMENT AND MASSIVELY PARALLEL SEQUENCING 
Maternal plasma (8–10 mL) was collected and prepared using the standard method as 
described previously (12). To construct the DNA library, we used the SureSelectXT Reagent 
Kit (Agilent Technologies, Santa Clara, CA) and 0.5–1 g of plasma DNA for each case. 
Because the library-preparation section in the SureSelect protocol is designed primarily for 
genomic DNA, we modified it by diluting all reagents in the kit to prepare the plasma DNA 
library. This protocol is better suited for small amounts of input DNA. The adapter-ligated 
DNA was purified directly with the spin columns provided in the QIAquick PCR Purification 
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Kit (Qiagen, Hilden, Germany) without further size selection. Four-cycle PCR and SureSelect 
primers were then used to amplify the adapter-ligated DNA. 
We quantified the DNA libraries using a Qubit 2.0 fluorometer (Invitrogen, Carlsbad, CA) 
and used the DNA 1000 Kit with a 2100 Bioanalyzer (Agilent) to check the size distribution 
of the libraries. We generated 0.3–0.5 g of an amplified plasma DNA library for each 
sample, with an approximate mean size of 270 base pairs. Targeted sequence enrichment was 
performed using the SureSelect Custom Kit (Agilent). The custom capture probes targeted 
entire transcribed DMD, ZFX, and ZFY regions according to four gene databases (RefSeq, 
Ensembl, CCDS, and GENCODE) and were designed using Agilent SureDesign 
(https://earray.chem.agilent.com/suredesign). The following parameters were used for the 
capture design sequences: density, 2 ; masking, least stringent; and boosting, balanced. We 
incubated 300 ng of the amplified plasma DNA library with the capture probes for 24 hours at 
65 °C, in accordance with the manufacturer’s instructions. After hybridization, we selected 
the captured targets by pulling down the biotinylated probe–target hybrids with streptavidin-
coated magnetic beads (Dynabeads M-280 Streptavidin; Invitrogen) and purified the targets 
using a MinElute PCR Purification Kit (Qiagen). Finally, we enriched the targeted DNA 
libraries using 12-cycle PCR amplification with SureSelect PCR primers (Agilent). The PCR 
products were purified using the QIAquick PCR Purification Kit. The library was paired-end 
sequenced on the Illumina HiSeq 2000 sequencing system. The sequenced paired-end reads 
were submitted to EBI European Nucleotide Archive (ENA) database with 
accession number PRJEB7629 (Direct access: http://www.ebi.ac.uk/ena/data/view/PRJEB
7629) 
VARIANT CALLING 
Paired-end sequencing reads were aligned to the human genome (Genome Reference 
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Consortium Human Reference 37) with Bowtie2 aligner (v.2.2.3) (13). Picard Tools 
(http://picard.sourceforge.net) was used to remove PCR-duplicated reads, and duplicate-free 
BAM files were indexed by using SAMtools (v.0.1.19) (14). Local realignment around small 
insertions and deletions (indels), and base quality score recalibration were achieved using the 
Genome Analysis Toolkit (GATK, v.3.2-2). Variant calling was performed using GATK 
HaplotypeCaller. We filtered out low-quality variant calls using GATK VariantFiltration with 
parameters described by GATK Best Practice (http://www.broadinstitute.org/gatk/guide/best-
practices) (154). Using our in-house script, we also filtered out variants with a genotype 
quality 30 and read depth 200. Lastly, we used ANNOVAR to annotate the unfiltered 
variants against the RefSeq gene set (16). 
STRUCTURAL VARIATION DETECTION 
Pindel (0.2.4.w) was used to detect structural variations (17). Only structural variations with a 
supportive read count 50, minimum length 1000 on the DMD gene were selected as 
pathogenic candidates. Compared with coverage plots visualized by the UCSC genome 
browser, large deletions/duplications were confirmed (18). 
HAPLOTYPE CONSTRUCTION 
Because of hemizygosity in males, we directly phased the maternal haplotypes of the DMD 
region. Using heterozygous single-nucleotide variants (SNVs) in the genomic DNA 
sequencing from the carrier mothers and probands, we classified the inherited haplotype that 
contained a deleterious mutation as haplotype A (HapA) and the other haplotype without a 
mutation as haplotype B (HapB). 
MEASUREMENT OF FRACTIONAL FETAL DNA CONCENTRATION 
In addition to the DMD gene, capturing the ZFX and ZFY genes provided a measurement of 
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the fractional fetal DNA concentration. Using mean read depth of two zinc finger genes 
( ZFX  and ZFY) with a minimum mapping quality score of 20 and base quality score of 20, 
we calculated the fractional fetal DNA concentration as:  







FETAL GENOTYPE PREDICTION 
The DMD gene is known to have a high recombination rate, and tests to detect the 
recombination event and recombination point were performed before fetal genotype 
prediction. To prevent the occurrence of a prediction error for the recombination point 
because of outlier values originating from duplicated or repetitive regions, we used the R 
package ‘qcc’ for outlier removal (19). After outlier detection, we predicted the change point 
in the read fraction values using the R package ‘bcp’ (Bayesian change point) (20). After 
detection of the recombination event, we reconstructed haplotypes with and without 
deleterious DMD mutations and designated these as HapA* and HapB*, respectively. 
Subsequently, we predicted the fetal genotype by identifying the allele fraction imbalance 
between two haplotypes obtained from maternal plasma sequencing. Because the inherited 
allele would be overrepresented in relation to the fetal DNA fraction in the maternal plasma, 
the fetal genotype was determined by estimating which haplotype was overrepresented. If the 
overrepresented haplotype was the one harboring the DMD mutation, the fetus could be 
predicted to have inherited the DMD mutation (Fig. 1). 
The statistical significance of the allele fraction imbalance was estimated using a one-tailed 
Student’s paired t test or Wilcoxon signed-rank test depending on the assumption of normality. 




CARRIER DETECTION FROM GENOMIC DNA SEQUENCING OF MOTHER AND 
PROBAND PAIRS 
Targeted deep sequencing of four mother and proband pairs revealed uniform coverage across 
the DMD gene. A summary of the basic sequencing of the four pairs is provided (Table 2.). 
Large deletions/duplications were identified on visual inspection from a coverage plot across 
the DMD gene in both probands and carrier mothers (Fig. 2). The breakpoints were estimated 
successfully using the structural variation detection software, Pindel. Using visual inspection 
and breakpoint estimation, the predicted deleted or duplicated exons in all pairs were 
identical to the previous results detected using the multiple ligation-dependent probe 
amplification method. In agreement with the previous result, probands with a deletion 
mutation had nearly zero read depth at the deletion site, whereas the carriers with a deletion 
mutation had about half the read depth compared with the baseline read depth outside the 
deleted region (DMD-01 and DMD-03). The read depth height of the carrier with a 
duplication mutation was positioned between that of the baseline and proband with a 
duplication mutation (DMD-02).  An inherited splice site mutation was also identified in the 
DMD-04-proband and the carrier mother (Fig. 3). The number of heterozygous or 
hemizygous SNVs in carriers and probands ranged from 700 to 1200 (Table 3). We 
successfully constructed two maternal haplotypes in the DMD gene using heterozygous 
SNVs and their proband haplotype. The mean read depth ratio of ZFY to ZFX ranged from 
0.95 to 0.98   in male probands and was 0 in female carriers, suggesting that these zinc 
finger genes could be used as a reliable indicator of the fractional cffDNA concentration in 
the subsequent study using maternal plasma (Table 4). 
FETAL GENOTYPE PREDICTION BY MATERNAL PLASMA DNA SEQUENCING 
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 Seven plasma DNA samples obtained from four pregnant carriers at different gestational 
weeks were sequenced. The sequencing results showed uniform and high coverage across the 
DMD gene (Fig. 4). The number of SNVs and indels were also compatible with the genomic 
DNA sequencing data (Table 5). Fractional cffDNA concentration estimated by calculating 
the mean read depth of ZFX and ZFY ranged from 5.8% to 9.7%. Higher duplicated read rates 
(18–28%) were noted in seven plasma samples used for DNA sequencing (Table 6). This 
difference may have originated from additional PCR cycles used during library preparation 
and target enrichment because of the low concentration of the input plasma DNA. 
Before examining the haplotype imbalance between the two phased maternal haplotypes, the 
recombination event within the DMD region was investigated using the R package, as 
described in Materials and Methods. The bcp algorithm estimated a significant change point 
in the read fraction in the sequencing data from DMD-02-9wk and DMD-02-12wk which 
were also evident from a scatterplot of the read fraction distribution of the phased haplotype 
(Fig. 5). Subsequent analysis suggested the recombination point between chromosomal X 
positions 32,321,115 and 32,346,373 based on the bcp algorithm. The haplotypes of DMD-
02-9wk and DMD-02-12wk sequencing data were reconstructed using the recombination 
point information. Because all the other plasma sequencing data revealed one large segment 
of two haplotypes, all remaining families, with the exception of DMD-02, used the same 
haplotype that was phased from the proband sequencing data (Fig. 6A–C).We next attempted 
to predict the fetal genotype by comparing the allele fraction between the two haplotypes in 
the maternal plasma. In both DMD-01-6wk and DMD-01-17wk, the allele fraction of HapB 
was significantly higher, indicating inheritance of the non-mutated haplotype by the fetus 
(Fig. 7A). All remaining samples supported the inheritance of a mutated haplotype by the 
fetuses, including DMD-02-9wk and DMD-02-12wk, the haplotype of which were 
reconstructed based on a recombination event prediction (Fig. 7B-D). All the allele fraction 
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differences and statistical test results are provided (Table 6). The fetal genotypes predicted 




















In the present study, we have demonstrated that targeted deep sequencing makes feasible not 
only genetic diagnosis of a DMD patient but also carrier detection and noninvasive prenatal 
diagnosis. Considering that the prenatal diagnosis of monogenic disorders is still performed 
in a family-based setting in which a genetically confirmed proband or carrier has been 
identified, this method has a practical advantage that proband diagnosis, carrier detection, and 
noninvasive prenatal diagnosis can be accomplished efficiently with a single platform. 
For clinical implementation of noninvasive prenatal diagnosis of X-linked recessive disorders 
including DMD, refining the detection method of dosage imbalance caused by presence of a 
small fraction of cffDNA is a critical step in identifying the maternally derived genotype. Tsui 
et al. used digital PCR to detect the slight overrepresentation of a F8 mutation in pregnant 
women who are carriers of hemophilia mutations (12). The relative mutation dosage analysis 
based on a sequential probability ratio test was used. Although it is simple and does not 
require haplotype information, the detecting probe must be individualized according to the 
specific mutation type. Further, multiple tests of each sample should be conducted to obtain 
sufficient statistical power, especially when the fetal DNA fraction is low, as in the early 
gestational weeks. Relative haplotype dosage analysis may be an alternative option for 
identifying the slight overrepresentation of an inherited maternal mutation or allele because 
the genome-wide or targeted massively parallel sequencing approach can produce many 
informative SNVs for haplotyping. Lam et al. used this approach to identify the maternal 
inheritance of a mutation in a -thalassemia model (9). Although -thalassemia is a disease 
with autosomal recessive inheritance, a method that identifies the maternal inheritance pattern 
would be equally applicable to X-linked recessive diseases. Instead of using the separate 
haplotyping method employed by Lam et al., New et al. sequenced a parent and patient trio, 
and then used the resulting haplotype information for maternal DNA analysis in the targeted 
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platform used in the trio analysis (11). This diagnostic flow could be incorporated more easily 
into the current genetic diagnosis and counseling process. 
Several gene-specific factors inherent to DMD should be considered for clinical 
implementation of noninvasive prenatal diagnosis. First, large deletion/duplication mutations 
constitute about two-thirds of the DMD mutation spectrum. Because a dosage imbalance 
already exists in DMD carriers with a large deletion/duplication mutation, it would be 
difficult to perform relative mutation dosage analysis using digital PCR. Thus, measuring the 
haplotype imbalance of the DMD region outside the mutation would be plausible. Second, the 
recombination rate of DMD is about four times higher compared with chromosome X and 
with the whole genome: 4.73 cM/Mb, 1.21 cM/Mb, and 1.26 cM/Mb, respectively (21, 22). If 
a recombination event occurred within the DMD region, it would greatly affect the dosage 
imbalance analysis and could result in an incorrect prediction. Fetal genotype prediction 
without considering the inheritance of recombinant haplotypes would cause nonsignificant 
haplotype imbalance or contradictory result; it is possible to misdiagnose a non-DMD fetus 
as harboring a DMD mutation and vice versa.  Thus, targeting the whole DMD region with a 
tiling design is preferable to ensure the reliable detection of a recombination event within the 
DMD region. Third, because the DMD region is hemizygous for male probands, all phased 
heterozygous SNVs are informative for dosage imbalance analysis provided that the 
recombination event is checked and corrected for before analysis. 
Considering the abovementioned gene-specific factors, we postulate that our approach 
targeting the whole DMD region with tiling design provide the best approach for noninvasive 
prenatal diagnosis of DMD. Instead of using multiple haplotype blocks for repeated relative 
haplotype dosage analysis (5, 11), we hypothesized that the whole DMD gene could be 
analyzed as one large haplotype block, and we compared directly the allele fractions of two 
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phased maternal heterozygous alleles. Although the study reported by New et al., in which 
multiple haplotype blocks were used, demonstrated the clinical applicability of that design to 
an array of autosomal recessive disorders, we believe that the current approach using one 
large haplotype block is a simpler and more straightforward method, at least for DMD. 
Although the fetal genotypes from all four DMD families were accurately predicted, the 
application of the current approach to routine molecular testing may have several limitations, 
in particular regarding noninvasive prenatal diagnosis. First, the current proband-based 
phasing approach may lead to misdiagnosis if separate recombination occurs both in a 
proband and in a new fetus. In addition, it was basically impossible to discern whether the 
recombination event observed in the DMD-02 family had occurred in the proband or in the 
new fetus using the current proband-based phasing approach, although the inherited fetal 
genotype could still be correctly predicted. This disadvantage could be partly overcome by 
adding the grandfather to maternal haplotype phasing, as the maternal X haplotype inherited 
from the grandfather would theoretically be free of recombination. This approach of using the 
grandparents for phasing was introduced in a recent article by Meng et al. (10) Second, as 
female patients or carriers of DMD mutations with no known proband have been increasingly 
identified, the current proband-based phasing approach also has a practical limitation in that 
setting. An alternative method that uses other family members for maternal haplotype phasing 
could be introduced to overcome this limitation, although it may still not be applicable to all 
at-risk couples without a proband. A grandfather or normal male child may be used for 
phasing via the same approach. Moreover, a carrier female or normal female child may also 
be used for phasing when the paternal genotype is available. Third, the optimal timing of 
testing and the least fetal DNA fraction required should be determined and validated in 
extended DMD families with various DMD mutations. In the current study, the earliest 
gestational time and the lowest fetal fraction that allowed successful noninvasive prenatal 
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diagnosis were 6 weeks and 5 days and 5.8%, respectively. New et al. reported a successful 
case of prenatal diagnosis at 5 weeks and 6 days of gestation with a fetal fraction of 1.4% 
(11). We believe that our results are compatible with those of the study performed by New et 
al. in terms of resolution, considering that 5 to 6 weeks of gestation might be the earliest 
period at which prenatal tests may be offered. However, data collection in extended families 
is needed, as the current study used only four families compared with the 14 families reported 
by New et al. Fourth, because the informative SNVs that are required for dosage imbalance 
analysis of maternally inherited alleles might be limited in number and located at greater 
distance, the current approach using one large haplotype block may be biased by false-
recombination prediction. Thus, the extension of the applicability of the current approach to 
autosomal recessive disorders should be demonstrated separately.  
Besides the technical considerations, there are complex ethical and socioeconomic issues to 
be addressed before such an approach can be implemented in the clinic. Currently, no 
curative therapy is available for DMD, although some therapeutic molecules are under 
clinical trial (23). However, considering the current method is best fitted to clinical 
circumstances in which the presence of an affected proband is the reason for prenatal testing, 
noninvasive determination of fetal genotype in the early gestational weeks could provide an 
autonomy-based reproductive option to the parents. 
Despite the need to overcome these various hurdles, our approach for the comprehensive 
genetic diagnosis of the proband and noninvasive prenatal diagnosis using a single massively 
parallel targeted sequencing platform may provide a practical model for implementation of 
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Table 1. DMD mutation status of the study cohort and types of samples sequenced. 
Study number 
DMD mutation 





(By MLPAa or Sanger sequencing) 
Probandb Mother   Proband Mother 
DMD-01 exon 49–52 deletion Carrier 
 
+ + + (6 wk 5d, 17 wk 1d ) + 
DMD-02 exon 2 duplication Carrier 
 
+ + + (9 wk 3d, 12 wk 1d) + 
DMD-03 exon 3-7 deletion Carrier 
 
+ + + (8 wk 5d, 11 wk 3d) + 
DMD-04 c.649+2T>C Carrier   + + + (7 wk 1d) + 
↵a MLPA, multiple ligation-dependent probe amplification. 






Table 2. Targeted massively parallel sequencing summary of genomic and maternal plasma DNA sequencing. 
Sample Total reads 
Total reads  
mapped to 
HG19 
Total reads  
mapped to 
HG19 (%) 
Total reads  
mapped to 
Target 









DMD-01-mother 67913844 67040224 98.71% 67913844 38.80 97.7 1211.23 
DMD-01-proband 68111649 67032588 98.42% 68111649 25.45 94.9 810.17 
DMD-01-fetus 62140714 61254461 98.57% 62140714 23.91 99.7 693.84 
DMD-02-mother 63394776 62700321 98.90% 63394776 41.04 97.7 1196.67 
DMD-02-proband 69839872 68993794 98.79% 69839872 26.96 99.6 880.73 
DMD-02-fetus 53482735 52826547 98.77% 53482735 21.04 99.7 527.45 
DMD-03-mother 66536460 65974792 99.16% 66536460 45.49 97.6 1316.77 
DMD-03-proband 30627950 30326923 99.02% 30627950 28.40 92.1 383.68 
DMD-03-fetus 33642168 33334631 99.09% 33642168 23.18 92.2 338.13 
DMD-04-mother 34191912 33941764 99.27% 34191912 49.51 97.4 744.87 
DMD-04-proband 32498580 32193877 99.06% 32498580 33.96 99 486.78 
DMD-04-fetus 29799572 29478604 98.92% 29799572 26.45 99.2 249.23 
DMD-01-6wk 54828936 53912045 98.33% 54828936 18.41 97.7 465.61 
DMD-01-17wk 53776131 52978358 98.52% 53776131 21.30 98 529.38 
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DMD-02-9wk 50420886 49643304 98.46% 50420886 18.91 98 440.4 
DMD-02-12wk 65047893 64180117 98.67% 65047893 26.40 98.6 792.31 
DMD-03-8wk 68397568 67646003 98.90% 68397568 37.79 98.3 698.06 
DMD-03-11wk 68874610 68144635 98.94% 68874610 37.89 98.9 724.04 
DMD-04-7wk 65317530 64610871 98.92% 65317530 38.70 98.1 687.24 





















DMD-01-mother 1459 1402 766 636 57 
DMD-01-proband 1066 1026 – 1026 40 
DMD-01-fetus 1057 1018 – 1018 39 
DMD-02-mother 1681 1631 1023 608 50 
DMD-02-proband 1209 1166 – 1166 43 
DMD-02-fetus 1192 1149 – 1148 43 
DMD-03-mother 1376 1326 724 602 50 
DMD-03-proband 1024 994 – 994 30 
DMD-03-fetus 1011 982 – 982 29 
DMD-04-mother 1656 1581 900 681 75 
DMD-04-proband 1106 1057 – 1057 49 
DMD-04-fetus 952 920 – 920 32 
DMD-01-6wk 1476 1415 781 634 61 
DMD-01-17wk 1482 1423 783 640 59 
DMD-02-9wk 1722 1662 1042 620 60 
DMD-02-12wk 1732 1678 1052 626 54 
DMD-03-8wk 1460 1408 761 647 52 
DMD-03-11wk 1456 1405 760 645 51 







Table 4. Mean read depth of two zinc finger genes and ZFX to ZFY ratio of the study 
samples. 
Sample 
Mean read depth 







DMD-01-mother 1150.06 0.92 0 – 
DMD-01-proband 779.27 759.14 0.97 – 
DMD-01-fetusa 637.27 621.54 0.98 – 
DMD-02-mother 1105.32 0.91 0 – 
DMD-02-pronband 794.58 770.91 0.97 – 
DMD-02-fetusa 504.52 491.97 0.98 – 
DMD-03-mother 1293.16 1.2 0 – 
DMD-03-proband 389.81 375.99 0.96 – 
DMD-03-fetus 333.72 322.74 0.96 – 
DMD-04-mother 649.85 0.75 0 – 
DMD-04-proband 454.98 435.24 0.95 – 
DMD-04-fetus 228.71 220.37 0.96 – 
DMD-01-6wk 442.57 12.88 0.04 5.6 
DMD-01-17wk 502.61 20.25 0.02 7.7 
DMD-02-9wk 412.21 20.01 0.04 9.2 
DMD-02-12wk 751.59 26.66 0.03 6.8 
DMD-03-8wk 677.24 22.17 0.03 6.3 
DMD-03-11wk 708.2 32.62 0.04 8.8 






Table 5. Duplicated read rate of the samples in the present study. 
Sample Total reads 






DMD-01-mother 67,913,739 73,055,256 5,141,517 7.03 
DMD-01-proband 68,111,501 72,365,082 4,253,581 5.87 
DMD-01-fetus 62,140,727 69,473,676 7,332,949 10.55 
DMD-02-mother 63,394,802 67,051,900 3,657,098 5.45 
DMD-02-proband 69,840,025 74,232,768 4,392,743 5.91 
DMD-02-fetus 53,482,707 59,063,358 5,580,651 9.44 
DMD-03-mother 65027479 66536460 1508981 2.26 
DMD-03-proband 30245725 30627950 382225 1.24 
DMD-03-fetus 32803261 33642168 838907 2.49 
DMD-04-mother 33577754 34191912 614158 1.79 
DMD-04-proband 32036957 32498580 461623 1.42 
DMD-04-fetus 26299406 29799572 3500166 11.74 
DMD-01-6wk 54,828,497 74,741,546 19,913,049 26.64 
DMD-01-17wk 53,776,065 72,911,708 19,135,643 26.24 
DMD-02-9wk 50,421,216 69,319,082 18,897,866 27.26 
DMD-02-12wk 65,047,677 80,532,264 15,484,587 19.22 
DMD-03-8wk 55738457 68397568 12659111 18.5 
DMD-03-11wk 56245002 68874610 12629608 18.33 
















Paired-difference tests (P-value) 





DMD-01-6wk 0.475 0.525 5 .0 5.8 <2.2e–16 < 2.2e–16 
DMD-01-17wk 0.471 0.529 5.6 8 <2.2e–16 < 2.2e–16 
DMD-02-9wka 0.522 0.477 4.4 9.73 <2.2e–16 < 2.2e–16 
DMD-02-12wka 0.514 0.485 2.9 7.1 <2.2e–16 < 2.2e–16 
DMD-03-8wk 0.528 0.472 5.6 6.3 <2.2e–16 < 2.2e–16 
DMD-03-11wk 0.525 0.475 4.9 8.8 <2.2e–16 < 2.2e–16 























Fig. 1. Illustration of the workflow of a comprehensive genetic diagnosis in a DMD 





Fig. 2. Coverage plots of genomic DNA sequencing data. 
Coverage plots of genomic DNA samples. Each position corresponding to a large 
deletion/duplication was completely matched in pairs. The red vertical bars represent the 79 




Fig. 3. Identification of single-nucleotide variants in DMD-04 pair. 




Fig. 4. Coverage plots of plasma DNA sequencing data. 
Coverage plots of plasma DNA samples. Four pregnant carriers at different gestational ages 
exhibited uniform coverage and identical deletions/duplications detected in genomic DNA 







Fig. 5. Detection of a recombination event and haplotype reconstruction in the DMD-02 
family. 
Read fraction distribution of two haplotypes. Each haplotype was divided into two large 
segments. The black dotted lines indicate the recombination point predicted by the bcp 





Fig. 6. Read fraction distribution of plasma samples without recombination events. 
The distribution of read fractions represents one large segment of each haplotype. (A) DMD-











Fig. 7. Fetal genotype prediction. 
(A) HapB is overrepresented in DMD-01 maternal plasma samples (allele fraction differences: 5.0% and 5.6%). HapA or HapA* are 
overrepresented in the remaining maternal plasma samples. (B) DMD-02 (allele fraction differences: 4.4% and 2.9%). (C) DMD-03 (allele 




Fig. 8. Fetal genotype validation. 
Fetal genotypes predicted using plasma DNA samples were successfully validated by fetal 
genomic DNA obtained via either chorionic villi sampling or amniocentesis. (A) Large 




배경: 산모혈장에 존재하는 태아 DNA와 차세대시퀀싱 기술을 결합하여 비침습
적 산전진단 방법을 개발하려는 연구가 활발히 진행되고 있다. 사전연구에서 차
세대시퀀싱을 이용한 Duchenne형 근이영양증의 유전진단 플랫폼을 개발한 바 
있는데, 이를 토대로 보인자 확인 및 비침습적 산전진단법 개발까지 확대 응용하
는 방법을 개발하고자 하였다. 
방법: 디스트로핀 유전자 전장을 포함하도록 타겟 지역을 설계하여 캡쳐 키트를 
제작하였다. 이미알려진 4명의 보인자 산모와 환자에서 보인자 상태의 진단이 가
능한지 차세대시퀀싱을 통해서 분석하였다. 상기 4가계에서 다양한 임신주수 에
서 산모 혈장을 수집하여 차세대시퀀싱 및 정해진 알고리듬에 따라 태아의 유전
형 예측이 가능한지 확인한다. 태아의 유전형은 산모의 두 하프로타입의 양을 수
치화 하여 비교하여 산모혈장 시퀀싱 데이터에서 양이 많은 하프로타입이 태아에 
전달된 것으로 예측한다. 하프로타입의 구분은 환자의 시퀀싱 데이터을 이용하고, 
이 때 유전자 재조합의 가능성을 고려하여 분석한다. 
결과: 상기 플랫폼을 이용하여 디스트로핀 유전자의 거대중복, 거대결실, 점돌연
변이 모두에서 산모의 보인자 상태를 정확하게 확인할 수 있었다. 산모혈장 시퀀
싱 데이터를 통해서도 4태아 모두에서 유전형을 정확하게 예측하였으며, 가장 일
찍 예측 된 임신주수는 6주 5일 이었다. 한 가계에서는 유전자 재조합이 발생한 
것이 확인 되었으며, 이를 토대로 교정한 후에 정확하게 예측이 가능하였다. 
결론: 산모혈장의 태아 DNA 및 차세대시퀀싱 방법을 이용하여 Duchene형 근이
영양증의 비침습적산전진단이 가능함을 증명하였다. 동일한 원리를 이용하여 X 
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연관 열성 유전양식의 기타 질환에도 확대적용을 기대할 수 있다. 
주요어: 비침습적 산전진단, Duchenne형 근이영양증, 태아 혈장 DNA, 차세대시
퀀싱 
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